Metsera has brought in over $500m in funding in just seven months as it looks to enter the competitive weight loss arena.
Adaptimmune’s Phase II IGNYTE-ESO trial investigating experimental T cell therapy lete-cel has achieved its primary endpoint.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback